OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - GENMAB | Real-time Boerse Frankfurt Warrants 01:24:28 26/06/2024 pm IST | ||
| 14.49 EUR | +0.14% |
|
| Current month | +14.57% | ||
| 1 month | +10.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 26/24/26 | 14.49 | +0.14% |
| 25/24/25 | 14.47 | +0.42% |
| 24/24/24 | 14.41 | -0.41% |
| 21/24/21 | 14.47 | -0.89% |
| 20/24/20 | 14.6 | -3.95% |
Real-time Boerse Frankfurt Warrants
Last update June 26, 2024 at 01:24 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SW8842 |
| ISIN | DE000SW88420 |
| Date issued | 19/04/2024 |
| Strike | 2,893 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 12.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.21 € |
|---|---|
| Lowest since issue | 11.03 € |
| Spread | 0.03 € |
| Spread % | 0.21% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,799
DKK
Average target price
2,464
DKK
Spread / Average Target
+36.96%
- Stock Market
- Certificates
- Certificat
